Industry Resource Partners (IRP)
Driving regenerative medicine research toward success
The CIRM Industry Resource Partners (IRP) Program forges beneficial partnerships between industry organizations and CIRM awardees to stimulate innovation and accelerate the development of novel therapies for the people who need them.
Under the umbrella of CIRM’s earlier Industry Alliance Program (IAP) established in 2018, the IRP program aims to strengthen the field by bolstering collaboration as CIRM-funded projects move towards commercialization.
Initially conceived as a part of CIRM’s strategic vision to deliver real-world solutions by overcoming potential bottlenecks in development, the IRP Program helps research advance through various stages—including discovery, translational, and clinical—in accordance with regulations.
CIRM Industry Resource Partners have provided critical resources including:
- Project consultation to aid CIRM applicants in drafting manufacturing plans and budgets
- Access to manufacturing resources for cell therapy, gene therapy, and biologics
- Access to innovative gene editing technology and cell lines
- Access to the company networks and expertise
Our partners have the opportunity to collaborate with CIRM and engage with CIRM awardees, to help advance the cell and gene therapy industry.
Current IRP members include:
Interested in learning more about CIRM’s IRP Program? Explore the benefits, eligibility, and requirements below and contact Thomas Trinh at ttrinh@cirm.ca.gov.
The Industry Resource Partnership (IRP)
The Industry Resource Partnership seeks to make collaboration easier and to streamline knowledge sharing between industry leaders and CIRM’s awardees. See below for the basic requirements and eligibility criteria set by CIRM for participating in the program.
- Feature on CIRM’s website as an Industry Resource Partner
- Exclusive invitation to attend CIRM’s annual symposia events (e.g. vendor shows)
- Opportunities to directly engage with potential clients (CIRM’s portfolio encompasses 200+ cell & gene therapy projects)
- Pre-approval inspection-ready Contract Development and Manufacturing Organization (CDMOs) facilities dedicated to cell and gene therapies
- Development and manufacturing services with experience producing current Good Manufacturing Practices (cGMP) materials under an IND
- Pre-clinical services with experience supporting GLP projects
- Bioanalytical capabilities to support non-clinical and clinical studies
- Repository services for clinical trial samples
- Services to provide strategic, technical, operational, and/or regulatory guidance to cell and gene therapy projects
- Services to support any stage of supply chain or cell sourcing
- Participant of the INFR5 Manufacturing Network
- Letter of recommendation from a CIRM awardee
Core requirements:
- Provide detailed proposals and letter of support to CIRM prospective awardees
- Host an annual knowledge sharing webinar accessible to CIRM grantees
Additional requirements:
- Willingness to serve as a potential advisor for Manufacturing Network
- Preferential pricing or risk/cost sharing proposals exclusively for CIRM awardees
- Sponsorship of CIRM Annual Symposium
- Provide internship or training opportunities to CIRM Education Programs or the INFR5 Manufacturing Network
- Serve as an advisor to one of CIRM’s Clinical Advisory Panels or other CIRM panel
Interested partners will be asked to provide a one-page summary of their services and to agree to at least two requirements by signing a Memorandum of Understanding (MOU) with CIRM.
